The appearance of Quantum BioPharma (NASDAQ: QNTM) in a national fitness publication marks a notable moment for the company's over-the-counter alcohol recovery product, but the coverage itself delivers a carefully balanced verdict that matters as much for what it questions as for what it reports. According to NEWMEDIAWIRE, the Men’s Fitness article by Lakshan Weeraratne examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum BioPharma (NASDAQ: QNTM) and licensed to Unbuzzd Wellness.
The study in question was a company-sponsored, placebo-controlled trial involving 26 healthy adults, 24 of whom completed both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. The most striking figure involved 17 participants identified as rapid responders: among them, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo.
That headline number helps explain why the product attracted national media attention and why the coverage matters to investors and consumers alike. A company-sponsored trial appearing in a mainstream fitness outlet lends visibility that a press release alone rarely achieves, potentially broadening awareness of the Unbuzzd brand and, by extension, the royalty stream Quantum retains. Under its agreement with Unbuzzd Wellness, Quantum receives royalty payments of 7% of sales until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026.
Yet the Men’s Fitness piece, as summarized in the release, devoted substantial space to the study's limitations: its small sample size, its company sponsorship and mixed results across broader measures of hangover severity and cognitive impairment. The article noted that larger, independent clinical trials are needed to confirm the findings and cautioned that increased alertness does not indicate sobriety or fitness to drive. Those caveats carry real implications. For a product marketed in the wellness space, independent replication is often the dividing line between a durable consumer franchise and a short-lived novelty, and the explicit warning against conflating alertness with sobriety addresses a public-safety concern that regulators and retailers are likely to watch closely.
The announcement thus functions less as a victory lap than as a positioning statement: it places Quantum's consumer asset in front of a mass audience while acknowledging the evidentiary gaps that remain. For investors tracking the company's broader portfolio, including its lead compound Lucid-MS for myelin degradation, the Unbuzzd coverage represents a separate, royalty-generating pathway whose commercial trajectory will depend on whether independent research validates the early signals. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and full terms of use and disclaimers applicable to the content are set out at https://IBN.ai/Disclaimer.
